Sai Life Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sai Life Sciences Limited reported strong full-year FY2026 results. Consolidated revenue grew 29.4% to Rs. 21,924.92 million from Rs. 16,945.70 million in FY2025. Profit after tax more than doubled to Rs. 3,489.10 million from Rs. 1,701.32 million, a 105% increase year-on-year. EBITDA margin expanded from approximately 25.6% to 30.3%. Finance costs reduced significantly from Rs. 761.64 million to Rs. 392.39 million, reflecting debt repayment from IPO proceeds. The company listed on NSE/BSE in December 2024 via an IPO raising Rs. 9,500 million in fresh capital; all IPO proceeds have been fully deployed for debt repayment and general corporate purposes. Auditors Deloitte Haskins & Sells LLP issued an unmodified opinion with no qualifications.
The company delivered exceptional double-digit growth in both revenue and profitability, with margin expansion indicating improved operational efficiency. The clean audit opinion and substantial debt reduction post-IPO are positive signals for shareholders.